Duroval is used across two distinct therapeutic domains and is considered relevant for easing symptoms. This medication is commonly used to help manage symptoms and is considered relevant for easing symptoms in both primary indications.

The medication is generally applied in situations involving certain distressing symptoms of Erectile Dysfunction (ED) and is also relevant for managing Pulmonary Arterial Hypertension (PAH). It helps address symptom clusters that may become disruptive, such as insufficient penile firmness, or physical symptoms like shortness of breath on exertion and fatigue.

“The medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

Supporting Function in Erectile Dysfunction (ED)

This application is relevant for easing symptoms related to Physiological Sexual Performance Impairment. Duroval is generally applied in situations involving distressing symptoms of ED, providing support that helps ease the overall symptom burden related to insufficient penile firmness. The medication assists with maintaining functional stability, and may assist with maintaining functional stability for sexual activity.

Quick Fact: Relief for Insufficient Firmness The medication is relevant for easing the symptoms of functional sexual impairment, which can interfere with daily functioning and intimate relationships, contributing to easing the overall symptom load during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Duroval — Official Regulatory Information

The eligibility profile for Duroval (Sildenafil) is defined by absolute prohibitions and specific restrictions outlined in governmental regulatory documentation. Eligibility is confirmed for Adult Males (Erectile Dysfunction) and Adults (Pulmonary Arterial Hypertension), including Geriatric Patients.

Populations For Whom Use Is Contraindicated:

• Patients concurrently using organic nitrates or riociguat (a guanylate cyclase stimulator).
• Patients with a known hypersensitivity to the drug.
• Patients with a history of vision loss due to non-arteritic anterior ischaemic optic neuropathy (NAION).
• Patients with severe hepatic impairment or recent history of stroke or myocardial infarction.
• Patients with hypotension (blood pressure less than 90/50 mmHg).

Age and Condition Restrictions: Use is contraindicated in pediatric patients for the Erectile Dysfunction indication. For Pulmonary Arterial Hypertension, use is not established in children under one year of age. Use is restricted in patients with severe renal impairment, and some regulatory labels advise caution for older adults. For pregnancy and lactation, use is generally avoided or permitted only when strictly necessary, as documented in official labeling.

Duroval Interactions with other medicines and products

This section outlines the documented drug and substance interactions for Duroval, based strictly on authoritative government regulatory information.

Contraindicated Combinations

Co-administration of Duroval is strictly prohibited (contraindicated) with certain substance classes due to the risk of severe hypotension (dangerously low blood pressure). These include all forms of nitric oxide donors and nitrates (e.g., organic nitrates), as well as Guanylate Cyclase (GC) stimulators, such as riociguat.

Exposure-Modifying and Pharmacodynamic Interactions

• CYP3A4 Inhibitors: Strong inhibitors of the Cytochrome P450 3A4 enzyme (e.g., ritonavir) significantly increase the systemic exposure of Duroval. A lower initial dose of Duroval should be considered if co-administration is unavoidable.
• Alpha-blockers: Concomitant use with alpha-blockers can lead to symptomatic hypotension. Patients should be stable on alpha-blocker therapy before starting Duroval. Symptomatic hypotension is most likely to occur within four hours of dosing.
• Other PDE5 Inhibitors: The safety and efficacy of combining Duroval with other PDE5 inhibitors have not been established; concomitant use is generally advised to be avoided.

Required Constraints

Interactions are defined by the need to manage either pharmacodynamic potentiation (additive hypotensive risk) or pharmacokinetic reduction of clearance. The most severe constraint is the absolute prohibition of use with all nitrate-containing products.

Duroval operates through a dual-action pharmacodynamic mechanism targeting the fundamental cellular processes of bone remodeling. The primary action involves selective, high-affinity binding to the Receptor Activator of Nuclear Factor kappa B Ligand ( RANKL) protein. This molecular interaction interrupts the signaling between osteoblasts and osteoclast precursors, which is required for differentiation. Consequently, the downstream cascade inhibits the maturation and functional activity of osteoclasts, the cells responsible for bone resorption. Furthermore, Duroval contributes to the anabolic pathway by modulating the intracellular Wnt/beta-catenin signaling pathway within osteoblasts. This modulation promotes their differentiation and increases the synthesis and mineralization of new bone matrix components. The combined effect on both resorption and formation cellular lines modulates the overall physiological balance of bone tissue turnover.

Duroval administration protocols are defined by distinct dosing and frequency requirements based on the specific indication being addressed. The medicine is approved for two main routes of delivery: oral (tablets or suspension) for routine use and intravenous (IV) bolus injection for the temporary continuation of treatment, primarily for pulmonary arterial hypertension (PAH) patients who cannot take oral medication.

Official Dosing and Frequency

The regulatory documents establish different schedules and maximum limits for each use.

For ED use, the medicine is administered as needed, typically 30 minutes to 4 hours before activity. Ingesting the tablet with a high-fat meal may lead to a delay in the onset of activity. The oral suspension requires reconstitution with water and must be vigorously shaken before administration.

Population-Specific Adjustments

Official labeling requires consideration of initial dose adjustments for specific patient populations. For the ED indication, a starting dose of 25 mg should be considered for older adults (≥ 65 years) and patients with severe renal (creatinine clearance <30 mL/min) or hepatic impairment. Furthermore, strict restrictions apply when Duroval is administered with certain interacting medications; for instance, the dose must not exceed 25 mg within a 48-hour period when used concurrently with ritonavir. The continuous PAH protocol dictates that a missed dose should be taken as soon as possible before resuming the fixed three-times-daily schedule.

Research Evidence / Overview of Studies for Duroval

Evidence for use in Erectile Dysfunction (ED)

The core research for Duroval in the context of Erectile Dysfunction (ED) is based on numerous short-term Randomized Controlled Trials (RCTs) and associated meta-analyses. These studies were used in research exploring how symptoms change over time by examining functional outcomes in adult males who reported insufficient penile firmness. The trials monitored patient-reported outcomes describing perceived discomfort and changes in the ability to achieve or maintain function related to sexual activity.

What the studies reported is that they observed measurements of functional outcomes that differed from those of placebo in the observed populations. The data report patterns related to symptom variability across a wide range of patients. Despite the volume of short-term data, long-term effects are not fully established.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

The PAH evidence base includes a mix of intermediate-term Randomized Controlled Trials (RCTs) and long-term observational studies. The main outcomes research monitored included changes in functional scales (like the 6-minute walk distance) and the time to key clinical events such as hospitalization or changes in survival status.

Studies reported measurements of both functional capacity and various markers of systemic or functional imbalance. Research highlights changes measured during the study period, with studies describing patterns where functional capacity was observed to change. Long-term studies monitored participants to assess survival and time to clinical worsening events; research provides insight into how these critical outcomes evolved in these severe, complex conditions.

What is Still Uncertain About Duroval Studies

One key limitation is that comparative evidence is lacking in terms of direct, randomized head-to-head trials against all other treatments in the PDE5 inhibitor class for ED. Furthermore, the most controlled data for PAH are centered on intermediate-term functional outcomes, and the long-term effects are not fully established by controlled studies alone. The certainty associated with the evidence varies across studies, particularly when moving from short-term RCTs to long-term observational data. Data for certain less common subgroups and specific disease etiologies, particularly within PAH, remain insufficient.

Common questions about Duroval (FAQ)

Q: How quickly does Duroval start working after taking it?

A: Duroval (sildenafil) is absorbed quickly into the bloodstream. According to official product information, when taken by mouth on an empty stomach, the medicine typically reaches its highest levels in the blood within 30 to 120 minutes.

Q: What does Duroval do to the body, generally speaking?

A: Duroval is classified as a selective phosphodiesterase type 5 (PDE5) inhibitor. Its fundamental action is to interrupt a specific enzyme, which enhances the smooth muscle relaxation caused by natural body signals. This mechanism results in the widening of blood vessels (vasodilation) and increased blood flow to targeted areas of the body.

Q: Can Duroval cause long-term side effects?

A: Most clinical trials used to establish the effectiveness and safety of Duroval were short-term studies. Official regulatory documents indicate that the long-term effects of the medication, particularly beyond the controlled study observation periods, are not fully established.

Q: Is it normal to feel [mild, non-specific symptom, e.g., slightly dizzy] when starting Duroval?

A: Yes, official safety information lists dizziness as a common side effect of Duroval (sildenafil). This is linked to the drug's properties as a vasodilator, meaning it relaxes blood vessels and can cause mild, temporary drops in blood pressure. If this occurs, it should be noted by the patient.

Q: Can alcohol be consumed safely while taking Duroval?

A: Regulatory documents describe a risk regarding alcohol consumption while using Duroval. Since Duroval is a vasodilator, it can temporarily lower blood pressure. Alcohol consumption may enhance this blood pressure-lowering effect, which could increase the risk of experiencing symptoms like dizziness, lightheadedness, or fainting.

Q: Can children or teenagers take Duroval?

A: Official labeling states that Duroval is not indicated for pediatric patients (children and teenagers) for the treatment of Erectile Dysfunction. However, for the Pulmonary Arterial Hypertension indication, the medication is approved for use in pediatric patients one year of age and older to help improve exercise ability.

Q: How long does Duroval typically stay in your system?

A: Duroval (sildenafil) and its primary active chemical byproduct are cleared from the body at a similar rate. Regulatory pharmacokinetics data shows that both have a half-life of approximately 4 hours, meaning it takes about that long for half of the substance to be eliminated.

Q: Will Duroval impact my ability to drive or operate machinery?

A: Because common side effects include dizziness and changes in vision (such as blurred or colored vision), regulatory labeling states that patients should be aware of how they react to the medication before driving or operating machinery.

Q: Is Duroval a generic drug, or is it only available as a brand name?

A: Duroval is a proprietary brand name for the medication. Its active ingredient is sildenafil, and this active ingredient is available in generic forms.

Q: What is the experience of people who have been on Duroval for a long time?

A: Studies on Duroval were primarily designed to assess short-term effects. While some long-term observational studies exist, particularly for the Pulmonary Arterial Hypertension indication, official regulatory documents state that the full long-term effects are not completely established by controlled data alone.

Q: Why do some people say they feel tired when taking Duroval?

A: Fatigue or tiredness is not listed as a common side effect in the primary clinical trials for the ED indication. However, its effect of lowering blood pressure can sometimes cause lightheadedness or general feelings of fatigue. Fatigue is also a common symptom of the condition Duroval treats (PAH).

Q: Can Duroval be split or crushed, or must it be swallowed whole?

A: Regulatory guidance on altering tablets generally applies to scored tablets or suspensions. If the Duroval tablet is not scored, it is typically taken whole. Only if the prescribing professional instructs otherwise should the tablet be altered.

Q: Does Duroval come in different strengths or forms (e.g., tablet, capsule)?

A: Yes, the official labeling shows that Duroval (sildenafil) is available in several forms and strengths. These include oral tablets (in multiple milligram doses), a powder for oral suspension, and an intravenous solution for hospital use.

Q: Is there a link between Duroval and changes in mood or sleep?

A: Official adverse reaction reports list insomnia, or difficulty sleeping, as a documented adverse event in clinical trials. Changes in mood are not listed as common or very common adverse effects in regulatory information.

Q: What are the signs of an allergic reaction to Duroval?

A: The official label notes that a known hypersensitivity (allergy) to the drug is a contraindication, meaning it should not be used. Signs of a serious allergic reaction may include rash, hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.

Q: How reliable is Duroval for the condition it treats?

A: Official clinical trial evidence confirms the effectiveness of Duroval (sildenafil). Studies for Pulmonary Arterial Hypertension showed that the drug improved patients' exercise ability and delayed clinical worsening compared to placebo. For Erectile Dysfunction, the trials demonstrated improvements in functional outcomes compared to placebo groups.

Q: Can Duroval be taken with antacids or acid reflux medication?

A: While there are no specific drug interactions listed for common antacids, regulatory data does show that taking the medicine with food can delay its rate of absorption. Some antacids are taken with food, which may mean that the medicine takes longer to reach its maximum concentration in the blood.

Q: What happens if I accidentally take too much Duroval?

A: Regulatory information on overdosage indicates that taking higher doses than recommended to healthy volunteers resulted in adverse events similar to those seen at standard doses. However, the events occurred more frequently and were generally more severe.

Q: Is it possible for Duroval to stop working after a while?

A: Regulatory documents do not use the term 'tolerance' or 'stop working.' However, studies tracking long-term use for PAH showed sustained benefits on clinical outcomes, but one measure (exercise ability) was not consistently maintained over the duration of the long-term study.

Q: What should I tell my dentist before a procedure if I'm taking Duroval?

A: Official patient counseling advice states that patients taking Duroval should inform all of their healthcare providers about their medication use. This includes dentists, especially before any procedures are performed.

Q: Why is Duroval taken at a specific time of day?

A: The timing of Duroval administration depends on the condition being treated. For the Erectile Dysfunction indication, it is taken as needed because its effects are related to the timing of sexual activity. For the chronic condition of Pulmonary Arterial Hypertension, it is taken at fixed intervals throughout the day to maintain a steady level of the medicine in the body.

Q: Does Duroval affect fertility in men or women?

A: Nonclinical toxicology studies in animals found no adverse effects on male or female fertility.

Official Storage and Disposal Requirements

Storage and disposal instructions for Duroval, which contains Sildenafil, are strictly defined by regulatory documents to ensure product stability and safety.

Storage Conditions

The medicine must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C. The product must be protected from moisture and kept in its original container, which must be tightly closed.

For the oral suspension form, the product is stable for 60 days after reconstitution and must be discarded after this period, even if properly stored.

Disposal and Child Safety

It is mandatory to keep the medicine out of the sight and reach of children. Unused or expired Duroval must be disposed of according to local regulations. Regulatory labeling strictly prohibits discarding the product via wastewater or household waste.